Characteristics of participants
familial dyslipidemia, epilepsy, puberty suppression, breast augmentation, depression
FAMILIAL HYPERCHOLESTEROLEMIA, EPILEPSY
Individuals who regularly visit the clinic are eligible to participate, provided that the individual started GAHT after 18 years of age (to eliminate potential effects of puberty suppression), received more than one year of GAHT, underwent vaginoplasty or orchiectomy (to avoid interference from androgen deprivation strategies), has sufficient knowledge of the Dutch language and a BMI 18–30 kg/m2. A potential subject who meets any of the following criteria will be excluded from participation in this study: previous use of progesterone/ progestin (not including cyproterone acetate or oral contraceptives), history of breast augmentation or reduction surgery, active treatment for depression, current use of progesterone/ progestin including cyproterone acetate, severe familial dyslipidemia (e.g. Familial Hypercholesterolemia), serum estradiol concentration > local reference range (200–400 pmol/L) at last visit prior to baseline, contraindications for the use of micronized progesterone, history of epilepsy (because of the oscillating 3D scanner).